multiple myeloma
Conditions
Interventions
experimental group:anti-BCMA CAR-T cells and anti-CD38 antibody
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-80 years; 2. Histologically/Immunohistochemistry confirmed CD38-positive and BCMA-positive multiple myeloma; 3. Patients who failed to receive chemotherapy for multiple myeloma or Patients with multiple myeloma recurrence; 4. ECOG performance status 0 to 2; 5. Patients without serious liver, kidney, heart and other diseases; 6. Patients who failed to receive autologous stem cells or allogeneic stem cells transplantation or Patients who are not suitable for the conditions of stem cell transplantation or who give up the transplantation due to the limitations of the conditions; 7. Patients who can understand and voluntarily sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Life expectancy < 3 months; 2. Pregnancy or lactation; 3. Patients with active hepatitis B or C infection; 4. Patients with mental or psychological diseases who can not cooperate with treatment and efficacy evaluation; 5. History of anaphylactic reaction to humanized or human antibodies or a Grade 3 or 4 administration reaction during a daratumumab administration; 6. The doctor thinks there are patients who cannot be included in the treatment for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;Overall remission rate;Progression Free Survival;Extramedullary infiltration; | — |
Countries
China
Contacts
Public ContactMingfeng Zhao
Tianjin First Central Hospital
Outcome results
None listed